文献速递免疫规划传染病防控与疫情报告

四价重组流感疫苗上市后安全性监测:VAERS报告分析

Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system.
PubMed 文献 · Vaccine · 2021-03-05

美国FDA于2016年批准四价重组流感疫苗(RIV4)用于18岁及以上人群。本研究回顾性分析了截至2020年6月30日VAERS收到的849份接种后不良事件报告,其中95%为非严重事件;严重事件包括10例吉兰-巴雷综合征(5例需机械通气、2例死亡),部分过敏反应虽报告为非严重但需干预。上市后监测对理解该疫苗获益与风险至关重要。

要点

  • RIV4接种后报告绝大多数为非严重事件(810/849,95%)。
  • 严重事件中报告10例吉兰-巴雷综合征,5例需机械通气,2例死亡。
  • 部分过敏反应报告为非严重但需肾上腺素等干预,2例重复接种后出现阳性再激发。

核心结论

  • RIV4上市后不良事件报告以非严重事件为主,但需关注吉兰-巴雷综合征和需干预的过敏反应。
  • 上市后安全性监测对持续评估RIV4的获益与风险至关重要。

研究设计与样本

  • 回顾性分析美国疫苗不良事件报告系统(VAERS)中截至2020年6月30日的RIV4接种后不良事件报告。
  • 共纳入849份报告,其中810份(95%)为非严重事件。

主要发现

  • 严重事件中报告10例吉兰-巴雷综合征,包括5例需机械通气、2例死亡。
  • 许多过敏反应报告为非严重,但需肾上腺素、雾化器、沙丁胺醇、糖皮质激素和补充氧气等干预。
  • 2例出现阳性再激发(重复接种RIV4后过敏反应),其中1例尽管预先使用抗组胺药仍出现呼吸困难、需肾上腺素并转急诊。

关键数值与推荐

  • RIV4于2016年10月7日获FDA批准,用于18岁及以上人群预防流感。
  • 临床试验未显示Flublok Quadrivalent与标准剂量四价灭活流感疫苗在不良事件或严重不良事件方面存在重大差异。

临床怎么用

  • 接种RIV4时应具备过敏反应应急处置能力,包括肾上腺素等。
  • 对曾有过敏反应者再次接种需谨慎评估,即使预先用药也可能发生严重过敏。
  • 吉兰-巴雷综合征等严重事件虽罕见,但接种后需监测神经系统症状。

局限性

  • VAERS为被动监测系统,报告可能存在漏报和报告偏倚。
  • 无法建立因果关系,报告率不能直接计算发生率。
  • 原文未报告对照人群或背景发生率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

On October 7, 2016, the Food and Drug Administration approved recombinant hemagglutinin quadrivalent influenza vaccine (RIV4) (Spodoptera frugiperda cell line; Flublok Quadrivalent) for active immunization for the prevention of influenza disease in individuals 18 years of age and older. Clinical trials did not reveal any major differences in adverse events or serious adverse events following Flublok Quadrivalent versus standard-dose quadrivalent inactivated influenza vaccine. To improve our understanding of the safety profile of this vaccine, we reviewed and summarized adverse event reports after Flublok Quadrivalent administration to the Vaccine Adverse Event Reporting System (VAERS). Through June 30, 2020, VAERS received 849 reports after RIV4 vaccination. The vast majority (810; 95%) were non-serious. Among serious events, there were 10 cases of Guillain-Barré syndrome, including 5 people who required mechanical ventilation and 2 people who died. Many allergic reactions were reported as non-serious, but required interventions to treat a life-threatening event, e.g., epinephrine, nebulizers, albuterol, glucocorticoids, and supplemental oxygen. Two people experienced a positive rechallenge (i.e., allergic reactions after repeated vaccination with RIV4), including a person who-despite premedication with antihistamines-developed respiratory difficulties, required epinephrine, and was transported to the emergency department. The occurrence of anaphylaxis and other allergic reactions in some individuals may reflect an underlying predisposition to atopy that may manifest itself after an exposure to any drug or vaccine, and does not necessarily suggest that Flublok Quadrivalent is particularly allergenic. Postmarketing safety surveillance will continue to be vital for understanding the benefits and risks of quadrivalent recombinant influenza vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Woo EJ, Moro PL. Postmarketing safety surveillance of quadrivalent recombinant influenza vaccine: Reports to the vaccine adverse event reporting system. Vaccine. 2021. PMID: 33678452. doi:10.1016/j.vaccine.2021.02.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。